Abstract：Objective：To observe the clinical effect of the therapy of Bailing Capsules combined with Febuxostat on uric acid nephropathy and its influence on serum inflammation. Methods ： A total of 68 patients with uric acid nephropathy were selected and divided into the Febuxostat group and the Bailing Capsules group according to random number table method，with 34 cases in each group. The Febuxostat group was treated with Febuxostat alone， and the Bailing Capsules group was additionally treated with Bailing Capsules based on the treatment of the Febuxostat group. Both groups were treated for two months. The clinical effects and adverse reactions in the two groups were compared，and the changes of kidney function indexes and serum inflammatory factors were compared before and after treatment. Results：The total effective rate was 94.12% in the Bailing Capsules group，higher than that of 76.47% in the Febuxostat group (P＜0.05). Before treatment，there was no significant difference in the comparison of the levels of blood urea nitrogen (BUN)，serum creatinine (SCr) and uric acid (UA) between the two groups (P＞0.05)；after treatment，the levels of UA，BUN and SCr in the two groups were decreased (P＜0.05)， and the above levels in the Bailing Capsules group were lower than those in the Febuxostat group (P＜0.05). Before treatment，there was no significant difference in the comparison of the levels of serum C-reactive protein (CRP)， interleukin- 6 (IL- 6) and tumor necrosis factor- α (TNF- α) between the two groups (P＞ 0.05)；after treatment，the levels of CRP，IL-6 and TNF-α in the two groups were decreased (P＜0.05)， and the above levels in the Bailing Capsules group were lower than those in the Febuxostat group (P＜0.05). Before treatment，there was no significant difference in the comparison of the traditional Chinese medicine (TCM) syndrome scores between the two groups (P＞0.05)；after treatment，the TCM syndrome scores in both groups were decreased (P＜0.05)，and the scores in the Bailing Capsules group were lower than those in the Febuxostat group (P＜0.05). There was no significant difference in the comparison of the incidence of adverse reactions between the two groups (P＞0.05). Conclusion： The therapy of Bailing Capsules combined with Febuxostat can improve the clinical effect on uric acid nephropathy，which can protect the kidney function of patients and reduce the levels of serum inflammatory factors without increasing adverse reactions，whose mechanism is related to the inhibition of inflammation in vivo.